🧾 What This Document Is

This is a Definitive Proxy Statement (DEF 14A). Think of it as an invitation and information packet for Amarin's shareholders. It's sent ahead of the Annual General Meeting (AGM) scheduled for May 13, 2026, to explain what will be voted on and provide key company details.

👉 Why it matters: This document lets shareholders exercise their ownership rights by voting on crucial company matters, from electing directors to approving major plans.

🏢 What The Company Does

In simple terms, Amarin is a pharmaceutical company focused on cardiovascular health.

Core Product: Its main drug is VASCEPA®/VAZKEPA® (the same drug, different brand names for different regions). This is a unique fish-oil-based therapy used to treat high triglycerides and reduce the risk of heart attack and stroke.
Business Model: The company is in a major transition. It has shifted from building its own global sales force to a partner-based model for international markets. This means it licenses the drug to regional partners who handle the selling, which drastically lowers Amarin's operating costs.
Key Market: It continues to defend its leadership in the U.S. market for its type of therapy (IPE therapy), even with generic competition.

💰 Financial Snapshot

The letter from the Chairman highlights Amarin's current financial standing:

Cash Position: $303 million in cash at year-end 2025.
Debt: $0 – no debt.
Cash Flow: Achieved positive cash flow in Q4 2025.
Cost Savings: A recent restructuring is expected to save $70 million annually.

🚀 Key Strategic Moves

The company is focused on three core strategies to create shareholder value:

Defend & Extend in the U.S.: Protect its market position for VASCEPA® against generics.
Grow Internationally with Partners: Fully transitioned to a partner model for VAZKEPA® in Europe and other markets. This allows global expansion without the huge cost of building commercial teams everywhere.
Maintain Financial Strength: Leveraging the strong cash position and cost savings to fund operations efficiently.

📦 Proposals for Shareholder Vote (The Main Event)

The AGM will vote on 13 proposals. Here’s the breakdown:

Routine Proposals (Need a simple majority "For"):

Proposals 1-7: Re-elect 7 directors to the Board (Aaron Berg, Patrice Bonfiglio, Keith Horn, Odysseas Kostas, Louis Sterling, Diane Sullivan, Michael Torok).
Proposal 8: Advisory (non-binding) approval of executive compensation ("Say on Pay").
Proposal 9: Re-appoint Ernst & Young LLP as auditors.
Proposal 10: Renew the Board's authority to issue new shares.
Proposal 11: Approve an amended 2020 Stock Incentive Plan to add 15 million more shares for employee awards.

Special Proposals (Need at least 75% "For" vote):

Proposal 12: Allow directors to be paid in stock instead of cash. The Chairman argues this aligns directors with shareholders and conserves cash.
Proposal 13: Allow the company to send future proxy materials electronically via its website instead of mailing paper copies. This is a cost-saving and environmentally friendly measure.

👉 Why these matter: Proposals 12 & 13 are highlighted as critical cash-saving initiatives by management. Their high voting threshold (75%) makes them more challenging to pass.

👥 Board & Governance

Board Changes: Two directors, Dr. Paul Cohen and Mr. Oliver O’Connor, are not standing for re-election and will leave the board.
Leadership: Odysseas Kostas, M.D. is the independent Chairman. Aaron Berg is the CEO and the only non-independent board member.
Committees: Key committees (Audit, Remuneration/Compensation, Nominating) are composed entirely of independent directors.
Executive Team: Key officers include Peter Fishman (CFO), David Keenan (COO), Steven Ketchum (R&D Chief), and Jonathan Provoost (Legal Chief).

📅 Key Dates & Details

Annual General Meeting: May 13, 2026, at 9:00 a.m. Dublin time (held at Arthur Cox LLP's offices).
Record Date: March 31, 2026. Only shareholders on this date can vote.
Voting Instructions Deadline (for ADS holders): May 8, 2026, at 9:00 a.m. New York time.
Contact for AGM: Shareholders planning to attend should email [email protected].

⚖️ Big Picture: Strengths & Risks

👍 Strengths: Strong balance sheet ($303M cash, no debt), strategic pivot to a lower-cost partner model, positive Q4 cash flow, and active cost-cutting.
⚠️ Risks: Dynamic and competitive U.S. generic market, reliance on partners for international success, and the need for high shareholder approval (75%) for key cost-saving proposals.

🧠 The Analogy

Amarin is like a homeowner who has paid off their mortgage and is now renting out rooms to carefully chosen tenants. This brings in steady income without the cost and hassle of managing the entire property alone, freeing up cash to maintain the core house (the U.S. business). Now, the homeowner is asking fellow co-owners (shareholders) to approve a plan to pay the building's board members with house shares instead of cash and to stop mailing paper statements, all to save money and keep the building financially strong.

🧩 Final Takeaway

Amarin is leveraging its strong, debt-free financial position to navigate a competitive market. It is asking shareholders to approve a shift to a leaner, partner-driven global model and to back specific cost-saving governance changes to preserve cash and align interests for the long term. The success of its international strategy and these key votes will shape its next chapter.

AMARIN CORP PLC\UK — DEF 14A Filing